Swiss drugmaker Roche won clearance from Britain's Competition and Markets ...
Roche wants to buy U.S.-based Spark to gain a foothold in gene therapy as well as add to its portfolio against hemophilia A, where the Basel-based company already has the treatment Hemlibra that is due to surpass $1 billion sales this year.
Britain’s competition agency came to the conclusion it would not, even as the U.S. Federal Trade Commission has yet to formally weigh in. The CMA said it had “cooperated closely” with the FTC.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
Analysis: The real reason Democrats should study the UK electionThe Labour Party's wipeout in Britain's election spelled out an undeniable warning to Democrats over the potential dangers of tracking too far to the left of more moderate national electorates | Analysis
続きを読む »
UK Labour's finance chief McDonnell to step down after election defeatBritain's opposition Labour party finance spokesman John McDonnell will not...
続きを読む »
What the U.K. Election Does (and Doesn’t) Teach Democrats'Now more than ever, opponents of rightwing nationalism must resist the temptation to project the clarity of our moral convictions onto empirical questions of political reality'
続きを読む »
UK PM Johnson must accept another Scottish independence vote: SturgeonBritish Prime Minister Boris Johnson needs to 'focus on reality' and r...
続きを読む »
'The fight carries on', anti-Brexit protester says after UK voteFor the last two years, demonstrator Steve Bray has become known for his protest...
続きを読む »
'I will repay your trust,' UK PM Johnson tells ex-Labour voters on trip to northPrime Minister Boris Johnson visited former strongholds of his Labour opponents ...
続きを読む »